Payload Information

General Information of This Payload
Payload ID
PAY0TWRKP
Name
Y90 (Radioactive isotope)
Synonyms
Yttrium-90; Yttrium Y-90; SIR-Spheres; 90Yttrium; 10098-91-6; Yttrium Y 90; Yttrium (90 Y); UNII-1K8M7UR6O1; Y-90; Yttrium, isotope of mass 90; 1K8M7UR6O1; Yttrium Radioisotopes; Yttrium-090; 90Y; 90Y radioisotope; Radioactive Yttrium; Y-90 radioisotope; Yttrium, radioactive; HSDB 7406; DTXSID40874005; YTTRIUM (90 Y) [WHO-DD]; DB13076; Y 90; Q2650092; D015021000
   Click to Show/Hide
Target(s) .
 Target Info 
Structure
Formula
Y
Isosmiles
[90Y]
PubChem CID
104760
InChI
InChI=1S/Y/i1+1
InChIKey
VWQVUPCCIRVNHF-OUBTZVSYSA-N
IUPAC Name
yttrium-90
The activity data of This Payload
Standard Type Value Units Cell line Disease Model Cell line ID Reference
Half Maximal Inhibitory Concentration (IC50) >3000 nM
RKO cells
Colon carcinoma
CVCL_0504 
[1]
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Rosopatamab tetraxetan [Clinical candidate]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Efficacy Data Objective Response Rate (ORR)
9.38% (breast cancer)
0.00% (gastric cancer)
Patients Enrolled
Unresectable, locally advanced or metastatic breast cancer or gastric cancer refractory to standard therapy.
Administration Dosage
Intravenously over 60 to 90 minutes at 0.05, 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.75, or 0.90 mg/kg every 3 weeks.
Related Clinical Trial
NCT Number NCT02576548  Phase Status Phase 1
Clinical Description
A phase 1/2 multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, pharmacokinetics, immunogencity, and antitumor activity of MEDI4276 in subjects with select HER2-expressing advanced solid tumors.
Primary Endpoint
In patients with breast cancer,ORR=9.38% (N=3/32),DOR=4.20-10.20 months. In the 0.05 to 0.40 mg/kg cohort,PFS=1.3-2.0 months. In the 0.50 to 0.75 mg/kg cohort,PFS=4.60-15.40 months. median overall survival (OS)=19.10 months (range 0.80-30.60, 95% CI 9.6-NA).
Other Endpoint
No objective responses in patients with gastric cancer,median PFS=1.80 months (range 0-10.7, 95% CI,1.3-3.0),median OS=6.50 months (range 2.80-16.30, 95% CI, 3.10-16.30).
Experiment 2 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT00070837  Phase Status Phase 1
Clinical Description
A phase 1/2 dose escalation trial of multiple doses of mLN2704 (DM1 conjugated monoclonal antibody mLN591) in subjects with metastatic androgen-independent prostate cancer.
Experiment 3 Reporting the Activity Date of This ADC [4]
Related Clinical Trial
NCT Number NCT00052000  Phase Status Phase 1
Clinical Description
Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.
References
Ref 1 Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety. Eur J Med Chem. 2010 Aug;45(8):3420-38. doi: 10.1016/j.ejmech.2010.04.032.
Ref 2 First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Mol Cancer Ther. 2021 Aug;20(8):1442-1453.
Ref 3 Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urol Oncol. 2016 Dec;34(12):530.e15-530.e21.
Ref 4 A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer; NCT00052000

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.